KR20100096077A - 에포틸론 또는 에포틸론 유도체 유발성 설사의 치료를 위한 코르티코스테로이드 - Google Patents

에포틸론 또는 에포틸론 유도체 유발성 설사의 치료를 위한 코르티코스테로이드 Download PDF

Info

Publication number
KR20100096077A
KR20100096077A KR1020107010102A KR20107010102A KR20100096077A KR 20100096077 A KR20100096077 A KR 20100096077A KR 1020107010102 A KR1020107010102 A KR 1020107010102A KR 20107010102 A KR20107010102 A KR 20107010102A KR 20100096077 A KR20100096077 A KR 20100096077A
Authority
KR
South Korea
Prior art keywords
epothilone
formula
agent
patient
prednisolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107010102A
Other languages
English (en)
Korean (ko)
Inventor
아난드히 랑가나탄 조리
파울 엠.제이. 맥쉬히
디르크 베버
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20100096077A publication Critical patent/KR20100096077A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020107010102A 2007-11-09 2008-10-15 에포틸론 또는 에포틸론 유도체 유발성 설사의 치료를 위한 코르티코스테로이드 Withdrawn KR20100096077A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98663507P 2007-11-09 2007-11-09
US60/986,635 2007-11-09

Publications (1)

Publication Number Publication Date
KR20100096077A true KR20100096077A (ko) 2010-09-01

Family

ID=40087318

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107010102A Withdrawn KR20100096077A (ko) 2007-11-09 2008-10-15 에포틸론 또는 에포틸론 유도체 유발성 설사의 치료를 위한 코르티코스테로이드

Country Status (11)

Country Link
US (1) US20100267682A1 (enExample)
EP (1) EP2222286A1 (enExample)
JP (1) JP2011503075A (enExample)
KR (1) KR20100096077A (enExample)
CN (1) CN101848708B (enExample)
AU (1) AU2008325016A1 (enExample)
BR (1) BRPI0820338A2 (enExample)
CA (1) CA2703792A1 (enExample)
MX (1) MX2010005119A (enExample)
RU (1) RU2010123028A (enExample)
WO (1) WO2009061587A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117663C2 (uk) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN109790584A (zh) * 2016-09-27 2019-05-21 梅奥医学教育及研究基金会 用于评价和治疗癌症的材料和方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US10705435B2 (en) 2018-01-12 2020-07-07 Globalfoundries Inc. Self-referencing and self-calibrating interference pattern overlay measurement
US11686576B2 (en) 2020-06-04 2023-06-27 Kla Corporation Metrology target for one-dimensional measurement of periodic misregistration
US11796925B2 (en) 2022-01-03 2023-10-24 Kla Corporation Scanning overlay metrology using overlay targets having multiple spatial frequencies
US12032300B2 (en) 2022-02-14 2024-07-09 Kla Corporation Imaging overlay with mutually coherent oblique illumination
US12422363B2 (en) 2022-03-30 2025-09-23 Kla Corporation Scanning scatterometry overlay metrology
US12487190B2 (en) 2022-03-30 2025-12-02 Kla Corporation System and method for isolation of specific fourier pupil frequency in overlay metrology
US12235588B2 (en) 2023-02-16 2025-02-25 Kla Corporation Scanning overlay metrology with high signal to noise ratio

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231894A (zh) * 1998-04-14 1999-10-20 陈水清 止泻栓
DE60229922D1 (de) * 2001-03-19 2009-01-02 Novartis Ag Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
CN100553634C (zh) * 2002-10-11 2009-10-28 达纳-法伯癌症研究公司 用于治疗多发性骨髓瘤的埃坡霉素衍生物
EP1773334A1 (en) * 2004-07-26 2007-04-18 Novartis AG Epothilone combinations

Also Published As

Publication number Publication date
WO2009061587A1 (en) 2009-05-14
US20100267682A1 (en) 2010-10-21
CA2703792A1 (en) 2009-05-14
AU2008325016A1 (en) 2009-05-14
CN101848708B (zh) 2013-01-02
CN101848708A (zh) 2010-09-29
RU2010123028A (ru) 2011-12-20
JP2011503075A (ja) 2011-01-27
BRPI0820338A2 (pt) 2017-05-02
EP2222286A1 (en) 2010-09-01
MX2010005119A (es) 2010-05-27

Similar Documents

Publication Publication Date Title
KR20100096077A (ko) 에포틸론 또는 에포틸론 유도체 유발성 설사의 치료를 위한 코르티코스테로이드
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
EP2269603B1 (en) Treatment of breast tumors with a rapamycin derivative in combination with exemestane
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
EP1605892A2 (en) Combination of an aldosterone receptor antagonist and an anti-diabetic agent
AU2004281708A1 (en) Treating bone-related disorders with selective androgen receptor modulators
AU2017279592A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
JP5416327B2 (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
US20070142266A1 (en) Combination comprising a P-gp inhibitor and an anti-epileptic drug
ZA200409137B (en) Combinations comprising epothilones and pharmaceutical uses thereof
US20040067918A1 (en) Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
JP6051315B2 (ja) 乾癬を処置するためのピドチモドの使用
US7998973B2 (en) Tivozanib and temsirolimus in combination
US20080262071A1 (en) Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder
US20220184083A1 (en) Use of an agent capable of inhibiting the activation of mait cells for the treatment of obesity and obesity-related disorders
US20080132568A1 (en) Compounds with anti-androgenic activity and the use thereof
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
KR20040107481A (ko) 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물
KR20120123667A (ko) 골다공증의 치료
Yue et al. Rational formulation of saponin and dexamethasone for the synergistic treatment of rheumatoid arthritis in vivo
US20030139430A1 (en) Use of organic compounds
WO2022104413A1 (en) Methods and compositions for treating female sexual interest and arousal disorder
AU2005283829A1 (en) Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
JP2005531622A5 (enExample)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100507

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid